Abstract
Background Myocardial infarction with no obstructive coronary arteries (MINOCA) and ischemia with no obstructive coronary arteries (INOCA), are female predominant conditions, with a lack of clinical trials guiding medical management for the common underlying vasomotor etiologies. Long-term outcomes of (M)INOCA patients following attendance at a women’s heart center (WHC) are lacking.
Methods Women diagnosed with MINOCA (n=51) or INOCA (n=112) were prospectively followed for 3 years at the Vancouver WHC. Baseline characteristics, diagnoses, chest pain type, major adverse cardiac events, hospital encounters, medications, and Seattle Angina Questionnaire (SAQ) responses were compared between baseline and 3 years. Chi-squared tests were used to compare categorical variables, with Students’ t-tests for continuous variables.
Results MINOCA patients had significantly more non-exertional chest pain and diagnoses of vasospasm than INOCA patients, who had more exertional chest pain and diagnoses of coronary microvascular dysfunction. Following baseline, both groups had significant reductions in cardiovascular emergency room visits, with INOCA patients also experiencing fewer cardiovascular hospitalizations. At 3 years, the most commonly prescribed medications were calcium channel blockers, long-acting nitrates and beta blockers, with MINOCA having more acetylsalicylic acid and INOCA more short-acting nitrates and ranolazine prescriptions. Both groups observed significant improvements in SAQ scores, with greater improvements observed in INOCA patients. Patients with depression or prescribed ranolazine at 3 years had worse SAQ scores at baseline.
Conclusions Three-year outcomes of (M)INOCA patients indicate that the WHC’s comprehensive care model effectively improves diagnostic clarity, reduces hospital encounters, optimizes medication management, and improves self-reported patient well-being.
Competing Interest Statement
E.T. has received honorarium for speaking engagements from Amicus Therapeutics. T.S. has received honorarium for speaking engagements and advisory boards from KYE pharmaceuticals, Sanofi, Amgen, Pfizer, HLS pharmaceuticals, Novartis, BI-Lilly and Novo Nordisk. The other authors do not have any financial disclosures.
Funding Statement
This work was supported through the 2022 BC Women's Hospital Women's Health Research Institute Catalyst Grant and support from the VGH Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical research ethics board of the University of British Columbia gave ethical approval for this work (application #H13-03322).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Co-first authors
Updated main text body, including new Table 5.
Data Availability
Data produced in this study are available upon reasonable request to the authors.
